Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Immune Anti-Inhibitor Market by Type (Recombinant Immune Anti-Inhibitor, Plasma-derived Immune Anti-Inhibitor, Others), By Application (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Immune Anti-Inhibitor Market by Type (Recombinant Immune Anti-Inhibitor, Plasma-derived Immune Anti-Inhibitor, Others), By Application (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 170964 3300 Pharma & Healthcare 377 238 Pages 4.5 (34)
                                          

Market Overview:


The global immune anti-inhibitor market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of autoimmune diseases, rising demand for biologics and growing awareness about autoimmune diseases. The global immune anti-inhibitor market is segmented on the basis of type, application and region. On the basis of type, the market is segmented into recombinant immune anti-inhibitors, plasma-derived immune anti-inhibitors and others. The recombinant immuneanti- inhibitors segment is expected to grow at a CAGR of 8% during the forecast period from 2018 to 2030 due to its high efficacy and safety profile as compared to other types of immuno suppressants available in the market.On themarketbyregion , North America accounts for majority share in terms of revenue followed by Europeand Asia Pacific .


Global Immune Anti-Inhibitor Industry Outlook


Product Definition:


An immune anti-inhibitor is a molecule that blocks the inhibitory activity of certain cells of the immune system, such as T regulatory cells. Blocking the inhibitory activity of these cells can help to boost or restore the function of the immune system in patients with autoimmune diseases or cancer.


Recombinant Immune Anti-Inhibitor:


Recombinant immune inhibitor is a new type of immunosuppressive drug. It's main function is to decrease the inflammatory response by inhibiting the release of interleukin (IL) - 1, tumor necrosis factor (TNF), and other cytokines which are responsible for inflammation. Recombinant immune inhibitors have been reported to produce fewer side effects than conventional drugs used for similar purposes.


Plasma-derived Immune Anti-Inhibitor:


Plasma-derived immune anti-inhibitor is a new term that refers to an inhibitor used by the body's immune system to prevent itself from overreacting and responding too strongly to foreign substances. The plasma-based anti-inhibitors are being studied for their ability to reduce the frequency of occurrence of autoimmune diseases including rheumatoid arthritis, psoriasis, lupus, etc.


Application Insights:


Based on the application, the global immune anti-inhibitor market is segmented into hospital pharmacies, online pharmacies and retail pharmacies. The hospital pharmacy segment dominated the overall industry in terms of revenue in 2017. This can be attributed to factors such as presence of a large patient base with chronic diseases requiring regular medication and rising prevalence of cancer which increases treatment costs significantly. Moreover, increasing number of research collaborations among key players for developing novel products specific to cancer patients will boost product demand over the forecast period.


The online pharmacy segment is expected to grow at a lucrative rate during the forecast period owing to growing internet usage rates coupled with easy access from different parts of world for purchasing drugs via credit/debit cards or e-checks through website operators' secure server network resulting in lesser opportunity for counterfeit drugs sold via grey market sources due to lack of direct contact with customers leading them towards safety & security while buying medicines online thereby boosting growth prospects over projected period.


Regional Analysis:


North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers, favorable reimbursement policies, and increasing healthcare expenditure are some factors contributing to its growth. In addition, growing awareness about COVID-19 is anticipated to fuel the regional demand for immune anti-inhibitor over the forecast period.


Asia Pacific is expected to witness lucrative CAGR during the forecast period owing to rising disposable income coupled with improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in COVID-19 positive cases has led governments across this region including China & Australia & New Zealand have taken several initiatives for raising funds from public or private entities for developing new treatment options against Covid-19 which is further expected to propel revenue generation over the next eight years (2018– 2030).


Growth Factors:


  • Increasing incidence of autoimmune diseases: The global autoimmune disease market is expected to grow at a CAGR of 6.5% from 2016 to 2021. This is primarily due to the increasing incidence of autoimmune diseases, such as rheumatoid arthritis, Crohn’s disease, and psoriasis. The immune anti-inhibitor market is expected to benefit from this growth in the autoimmune disease market.
  • Growing awareness about immunosuppressants: There is growing awareness among patients and healthcare professionals about the benefits of using immunosuppressants for treating various immune-mediated disorders. This is likely to drive demand for immune anti-inhibitors in the coming years.
  • Technological advancements in antibody engineering: There have been significant advances in antibody engineering over the past few years, which has led to the development of novel and more effective therapies for treating various immune-mediated disorders. This is likely to boost demand for immune anti-inhibitors in the coming years.

Scope Of The Report

Report Attributes

Report Details

Report Title

Immune Anti-Inhibitor Market Research Report

By Type

Recombinant Immune Anti-Inhibitor, Plasma-derived Immune Anti-Inhibitor, Others

By Application

Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

By Companies

Shire, Baxter, Roche, Novo Nordisk, CSL

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

238

Number of Tables & Figures

167

Customization Available

Yes, the report can be customized as per your need.


Global Immune Anti-Inhibitor Market Report Segments:

The global Immune Anti-Inhibitor market is segmented on the basis of:

Types

Recombinant Immune Anti-Inhibitor, Plasma-derived Immune Anti-Inhibitor, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Shire
  2. Baxter
  3. Roche
  4. Novo Nordisk
  5. CSL

Global Immune Anti-Inhibitor Market Overview


Highlights of The Immune Anti-Inhibitor Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Recombinant Immune Anti-Inhibitor
    2. Plasma-derived Immune Anti-Inhibitor
    3. Others
  1. By Application:

    1. Hospital Pharmacies
    2. Online Pharmacies
    3. Retail Pharmacies
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Immune Anti-Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Immune Anti-Inhibitor Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Immune anti-inhibitor is a medication that helps the body's immune system fight infection. It can be used to treat a variety of infections, including colds, flu, and other respiratory illnesses.

Some of the major players in the immune anti-inhibitor market are Shire, Baxter, Roche, Novo Nordisk, CSL.

The immune anti-inhibitor market is expected to register a CAGR of 7.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Immune Anti-Inhibitor Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Immune Anti-Inhibitor Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Immune Anti-Inhibitor Market - Supply Chain
   4.5. Global Immune Anti-Inhibitor Market Forecast
      4.5.1. Immune Anti-Inhibitor Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Immune Anti-Inhibitor Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Immune Anti-Inhibitor Market Absolute $ Opportunity

5. Global Immune Anti-Inhibitor Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Immune Anti-Inhibitor Market Size and Volume Forecast by Type
      5.3.1. Recombinant Immune Anti-Inhibitor
      5.3.2. Plasma-derived Immune Anti-Inhibitor
      5.3.3. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Immune Anti-Inhibitor Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Immune Anti-Inhibitor Market Size and Volume Forecast by Application
      6.3.1. Hospital Pharmacies
      6.3.2. Online Pharmacies
      6.3.3. Retail Pharmacies
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Immune Anti-Inhibitor Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Immune Anti-Inhibitor Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Immune Anti-Inhibitor Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Immune Anti-Inhibitor Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Immune Anti-Inhibitor Demand Share Forecast, 2019-2026

9. North America Immune Anti-Inhibitor Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Immune Anti-Inhibitor Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Immune Anti-Inhibitor Market Size and Volume Forecast by Application
      9.4.1. Hospital Pharmacies
      9.4.2. Online Pharmacies
      9.4.3. Retail Pharmacies
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Immune Anti-Inhibitor Market Size and Volume Forecast by Type
      9.7.1. Recombinant Immune Anti-Inhibitor
      9.7.2. Plasma-derived Immune Anti-Inhibitor
      9.7.3. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Immune Anti-Inhibitor Demand Share Forecast, 2019-2026

10. Latin America Immune Anti-Inhibitor Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Immune Anti-Inhibitor Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Immune Anti-Inhibitor Market Size and Volume Forecast by Application
      10.4.1. Hospital Pharmacies
      10.4.2. Online Pharmacies
      10.4.3. Retail Pharmacies
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Immune Anti-Inhibitor Market Size and Volume Forecast by Type
      10.7.1. Recombinant Immune Anti-Inhibitor
      10.7.2. Plasma-derived Immune Anti-Inhibitor
      10.7.3. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Immune Anti-Inhibitor Demand Share Forecast, 2019-2026

11. Europe Immune Anti-Inhibitor Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Immune Anti-Inhibitor Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Immune Anti-Inhibitor Market Size and Volume Forecast by Application
      11.4.1. Hospital Pharmacies
      11.4.2. Online Pharmacies
      11.4.3. Retail Pharmacies
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Immune Anti-Inhibitor Market Size and Volume Forecast by Type
      11.7.1. Recombinant Immune Anti-Inhibitor
      11.7.2. Plasma-derived Immune Anti-Inhibitor
      11.7.3.Others
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Immune Anti-Inhibitor Demand Share, 2019-2026

12. Asia Pacific Immune Anti-Inhibitor Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Immune Anti-Inhibitor Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Immune Anti-Inhibitor Market Size and Volume Forecast by Application
      12.4.1. Hospital Pharmacies
      12.4.2. Online Pharmacies
      12.4.3. Retail Pharmacies
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Immune Anti-Inhibitor Market Size and Volume Forecast by Type
      12.7.1. Recombinant Immune Anti-Inhibitor
      12.7.2. Plasma-derived Immune Anti-Inhibitor
      12.7.3. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Immune Anti-Inhibitor Demand Share, 2019-2026

13. Middle East & Africa Immune Anti-Inhibitor Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Immune Anti-Inhibitor Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Immune Anti-Inhibitor Market Size and Volume Forecast by Application
      13.4.1. Hospital Pharmacies
      13.4.2. Online Pharmacies
      13.4.3. Retail Pharmacies
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Immune Anti-Inhibitor Market Size and Volume Forecast by Type
      13.7.1. Recombinant Immune Anti-Inhibitor
      13.7.2. Plasma-derived Immune Anti-Inhibitor
      13.7.3. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Immune Anti-Inhibitor Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Immune Anti-Inhibitor Market: Market Share Analysis
   14.2. Immune Anti-Inhibitor Distributors and Customers
   14.3. Immune Anti-Inhibitor Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Shire
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Baxter
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Roche
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Novo Nordisk
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. CSL
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. COMPANY6
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. COMPANY7
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. COMPANY8
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. COMPANY9
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. COMPANY 10
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us